Factor lXTsipds is a factor IX variant from a hemophilia B patient with reduced levels of circulating protein molecules (cross-reacting material reduced, CRM'). This variant contained a glycine (Gly) t o glutamic acid (Glu) substitution at the 207th codon of mature factor IX. The functional consequences of the Gly -+ Glu mutation in factor IXTaiPiS (IXG207E) were characterized in this study. Plasma-derived IXG207E exhibited a mobility similar to that of normal factor IX on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Its specific activity was estimated t o be 3.5% that of the purified normal factor IX in a one-stage partial thromboplastin time assay (aPlT). Cleavage of factor IXG207E by factor Xla or factor Vlla-tissue factor complex appeared t o be normal. When the calcium-dependent conformational change was examined by monitoring quenching of intrinsic fluorescence, both normal factor IX and IXG207E exhibited aquivalent intrinsic fluorescence quenching. Activated factor ACTOR IX (CHRISTMAS FACTOR) is a plasma glycoprotein belonging to the serine protease family. It participates in the intrinsic coagulation pathway and is involved in normal hemostasis. A deficiency of factor LX results in the clinical syndrome, hemophilia B, which is an X-linked inherited bleeding disorder. Factor IX-deficient patients are a heterogeneous group as defined by their plasma protein levels [normal (positive cross-reacting material; C M c ) , reduced ( C M ) , and undetectable (CRM-)], or by their gene mutations. A distinct subset of hemophilia B called hemophilia Bm is characterized by prolonged ox brain prothrombin time.' The Bm patients usually exhibit normal or reduced levels of abnormal factor IX antigens with nearly no clotting activities.
By Shu-Wha Lin, Chia-Ni Lin, Nobuko Hamaguchi, Kenneth J. Smith, and Ming-Ching Shen Factor lXTsipds is a factor IX variant from a hemophilia B patient with reduced levels of circulating protein molecules (cross-reacting material reduced, CRM'). This variant contained a glycine (Gly) t o glutamic acid (Glu) substitution at the 207th codon of mature factor IX. The functional consequences of the Gly -+ Glu mutation in factor IXTaiPiS (IXG207E) were characterized in this study. Plasma-derived IXG207E exhibited a mobility similar to that of normal factor IX on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Its specific activity was estimated t o be 3.5% that of the purified normal factor IX in a one-stage partial thromboplastin time assay (aPlT). Cleavage of factor IXG207E by factor Xla or factor Vlla-tissue factor complex appeared t o be normal. When the calcium-dependent conformational change was examined by monitoring quenching of intrinsic fluorescence, both normal factor IX and IXG207E exhibited aquivalent intrinsic fluorescence quenching. Activated factor ACTOR IX (CHRISTMAS FACTOR) is a plasma glycoprotein belonging to the serine protease family. It participates in the intrinsic coagulation pathway and is involved in normal hemostasis. A deficiency of factor LX results in the clinical syndrome, hemophilia B, which is an X-linked inherited bleeding disorder. Factor IX-deficient patients are a heterogeneous group as defined by their plasma protein levels [normal (positive cross-reacting material; C M c ) , reduced ( C M ) , and undetectable (CRM-)], or by their gene mutations. A distinct subset of hemophilia B called hemophilia Bm is characterized by prolonged ox brain prothrombin time. ' The Bm patients usually exhibit normal or reduced levels of abnormal factor IX antigens with nearly no clotting activities.
Circulating factor IX is a zymogen of 415 residues, which contains several At the amino terminus, a Gla domain, containing 12 y-carboxyglutamic acid (Gla) residues, is thought to be responsible for the calcium-mediated binding of factor IX to phospholipids or platelets.'" Binding of metal ions induces conformational changes that are required for normal activity.'"" These conformational changes can be monitored by the quenching of intrinsic fluorescence of tryptophan residues.'*." The Gla domain is followed by IXG207E ilXaG207E) also binds antithrombin It1 equally as well as normal factor IXa. However, aberrant binding of the active site probe paminobenramidine was observed for factor Xla-activated factor IXG207E, indicating that the active site pocket of the heavy chain of factor IXaG207E was abnormal. Moreover, the rate of activation of factor X by factor IXaG207E, as measured in a purified system using chromogenic substrates, was estimated t o be 1/40 of that of normal factor 1Xa. A computer-modeled heavy-chain structure of factor IXa predicts a hydrophobic environment surrounding Gly-207 and this Gly forms a hydrogen bond t o the active site serine-365. The molecular mechanism of the Gly -+ Glu mutation in factor I XT. i p. o might result in the alteration of the microenvironment of the active site pocket which renders the active site serine-365 inaccessible to its substrate. 0 1994 by The American Society of Hematology.
two epidermal growth factor-like domains whose functions are not clear. The carboxyl terminus of factor IX is a serine protease domain containing a catalytic triad of histidine, aspartic acid, and serine, which are homologous to trypsin, chymotrypsin, and thrombin.14 Factor IX becomes an active enzyme after cleavage by factor XIa or the factor VIIa-tissue factor (VIIa-TF) ~o m p l e x '~ at two activation sites: Arg-Ala (residues 145 and 146) and kg-Val (residues 180 and 181), resulting in the release of an activation peptide (molecular weight, 10 kD). Activated factor IX (factor IXa; molecular weight, 45 kD) consists of a light chain (amino terminus) and a heavy chain (protease domain) connected by a disulfide bond.I6 Upon proteolysis, structural rearrangements of the serine protease domain occur that are mediated by the newlygenerated amino terminus of the heavy chain. It is proposed, in analogy to trypsinogen activation, that the first two amino acids (residues 181 and 182) of the heavy chain of factor IX flip into the activation pocket." This conformational change allows binding of the active site inhibitor, p-aminobenzamidine, the macromolecular inhibitor, antithrombin 111, and the substrate, factor Factor IXa subsequently activates factor X to generate activated factor X (factor Xa). The rate of this reaction is greatly enhanced by several cofactors; CaC12, phospholipids, and factor VIIIa.
To date, a variety of factor IX mutations have been found and characterized at the genetic level," yet not many of them have been analyzed to unveil the mechanisms by which these mutations contribute to the dysfunction of factor IX molecules. We have identified the genetic abnormality of a CRM' hemophilia B patient with a severe bleeding tendency. The mutant, designated factor IXTaipe19, has a point mutation at the 207th codon of factor IX; glycine (Gly) has been replaced by a glutamic acid (Glu) at this position.*' In an attempt to elucidate the molecular mechanism of this defective factor IX (factor IXG207E), we have purified factor IXG207E and studied the biochemical effects of this mutation from various perspectives. The molecular defect of factor MTdp.i9 has been determined previously by the polymerase chain reaction combined with direct sequencing?' A single nucleotide transition (guanine to adenine) at residue 30,073 was identified for this factor M variant, causing a glycine (G) to glutamic acid (E) substitution at the 207th codon (MG207E).
MATERIALS AND METHODS

Patienf
Purification of factor IX (or IXG207E) and enzyme-linked immunosorbent assay (ELBA). Collection of patient's plasma was performed after appropriate informed consent at a time when the patient had not been transfused with factor M for at least 4 weeks. Plasma factor M was purified by binding to a diethyl aminoethyl-sepharose CL-6B and a metal ion-dependent antifactor M monoclonal antibody (or factor IXG207E) was 1.14 to 1.5 NmoVL. Aliquots from the reaction mixtures were withdrawn at timed-intervals, placed in a solution containing 1% SDS, dithiothreitol, 2 mmol/L 2-mercaptoethanol, and 2 mmol/L EDTA, and subsequently subjected to SDSl PAGE analysis followed by silver staining or immunoblotting as described above.
Fluorescence quenching. Factor IX and IXG207E were titrated by adding appropriate amounts of increasing concentrations of CaClz as de~cribed.'~.'~ The concentration of either protein was 250 nmoV L and the fluorescence quenching was evaluated on a Jasco model FP-777 fluorescence spectrophotometer (Jasco, Tokyo, Japan). The excitation wavelength was 280 nm and the emission was measured at 340 nm.
Binding of p-aminobenzamidine. Factor IX or IXG207E (250 nmol/L) was activated by factor XIa (U40 of factor IX zymogen) as described2'." in the presence of 150 nmol/L p-aminobenzamidine plus 0.5% polyethylene glycol-6oO0, 10 ng/mL human serum albumin, and 5 mmol/L CaClZ in Tris-buffered saline (TBS; 20 mmoV L Tris-Cl, pH 7.2 and 100 mmol/L NaCl). The reaction mixtures were placed at 37°C in a l-mL fluorescence cuvette. Excitation was at 336 nm and emission was at 376 nm using the same spectrophotometer (above) equipped with a thermo-controller. Aliquots of the reaction mixtures were also removed at timed intervals and analyzed Antithrombin III (ATIII) binding. Approximately 0.1 to 0.3 Ng of factor XIa-activated factor IX or MG207E (designated MaG207E) was incubated with 0.1 ng of ATIII (Sigma Chemical CO, St Louis, MO) in the presence of heparin for 10 minutes before SDS-PAGE analysis under nonreducing conditions. The gels were silver stained or electrotransferred and immunoblotted with antifactor IX or antihuman ATIII antibodies.
Factor X activation kinetics. Activation of factor X by factor E a (or IXaG207E) was analyzed by monitoring kinetically the sequential hydrolysis of a chromogenic substrate (Spectrozyme Xa; Sigma) at 37°C in a spectrophotometer equipped with a thermal controller (Hitachi U-3OOO; Hitachi, Tokyo, Japan). The concentration of the enzymes was 4 nmol/L or 250 nm0I.L. In addition, the reaction mixtures contained 600 nmol/L of factor X (Enzyme Research Laboratory, South Bend, IN), 300 nmom Spectrozyme Xa, 10 mmol/L CaC12, and 12 pL phospholipids (Behring). The reaction rate was calculated according to the following equationz9: A b s = a2 + Vot, where a is the acceleration rate,Ab5 is the absorbance at 405 nm minus the initial value (&5(oJ and Vo is the rate of Spectrozyme Xa hydrolysis in the absence of factor X. Calculation was performed using the SAS program (SAS Institute, Cary, NC). Molecular modeling. To predict the structure of a zymogen form of factor M, a factor IXa model was modified at the activation site (residues 181 and 182) and residues in contact with it based on an xray crystallographic structure of trypsinogen (PDBlTGC.ENT)?D.3' This model was further modified to create a model for factor MG207E, where its Gly at the 207th position was replaced by Glu. Both models were energy minimized using AMBER 3.1A to reduce unfavorable contacts introduced by changes. All calculations and molecular dynamics were performed as des~ribed.'~,~'
by SDS-PAGE.
RESULTS
Biochemical characteristics of factor IXG207E. Because the antigen level of the patient's circulating factor IX was 30% to 40% of normal, purification of enough quantities of factor IXG207E was aided by binding of the plasma zymogen to a metal ion-dependent conformational specific antifactor IX antibody column that has been used previously to isolate normal and abnormal factor Isolated factor IXG207E, when analyzed by SDS-PAGE under reducing condition, ran as a single band with a mobility similar to that of normal factor IX purified by the same procedure ( Fig 1A) . Factor IXG207E was also recognized by several monoclonal antifactor IX antibodies A-l (recognizing the activation peptide), A-4, and A-5 (both recognizing the heavy chain of factor K), as shown by ELISA and by immunoblotting (Fig 1B) . This indicates that the global structure of the protein molecules are macroscopically similar to plasmaderived normal factor IX. However, purified factor IXG207E molecules were not functionally active as measured by the one-stage apTT assays using factor IX-deficient plasma. Its specific activity was to be 3.5% that of purified normal factor
IX.
Interaction of factor lXG207E with factor XIa and factor VIZ-TF complex. followed. Figure 2 depicts the activation by factor XIa at an enzyme to substrate ratio of I : 120. As shown on panel B, the signals for the intact factor IX and IXG207E decreased with a concomitant increase of signals for both the light and heavy chains. Activation by factor VIIa-TF complex yielded similar results. It appears that the mutation at the 207th codon in factor IXTa,iF,c) does not affect its activation by factor XIa or factor VIla-TF complex.
Fluorescence quenching. The ability of factor IXG207E to undergo a metal-induced conformational transition was evaluated by monitoring the effects of calcium on the quenching of intrinsic fluorescence. Titration of IXG207E with calcium resulted in a decrease in fluorescence that was similar to that observed with native factor IX (Fig 3) . Halfmaximal transitions were observed at about 0.6 mmol/L calcium. The result suggests that in the presence of increasing concentrations of calcium, factor IXG207E is able to undergo the conformational change monitored by the quenching of intrinsic tryptophan fluorescence.
Structural onalyis of factor IXG207E-Interaction of parninohenzarnidine. Binding of p-aminobenzamidine to the active sites of activated factor IX (IXa) or IXG207E (IXaG207E) were examined by monitoring the change in fluorescence of p-aminobenzamidine upon activation of both proteins by factor Xla."' The extent of exposure of the active site is proportional to the relative increase in fluorescence. The experiments were performed in the presence of human serum albumin as a stabilizer that had been determined to Activation by factor Xla. The activation by factor Xla was performed in the presence of CaCI,. Aliquots of 1.2 p g of each protein were activated by factor Xla in the presence of 5 mmollL CaCI, at a substrate t o enzyme ratio of 1201. At each time point, samples were withdrawn and added t o a solution of 1% SDS, 5 mmollL EDTA, and 4% 0-mercaptoethanol, boiled and then analyzed by SDS-PAGE. After electrophoresis, the proteins were visualized by silver staining. have no effect on the results (unpublished results). As shown in Fig 4A. whereas normal factor IX, upon activation by factor XIa, binds p-aminobenzamidine normally and exhibits an increase in fluorescence intensity, there was no increase in the level of fluorescence over the time course shown, and therefore, no exposure of a "normal" active site of IXaG207E. Both proteins were cleaved by factor XIa normally (Fig 4B) throughout the fluorescent measurement. Failure to bind p-aminobenzamidine by IXaG207E suggests an abnormal conformation of the active site pocket. For personal use only. on August 30, 2017. by guest www.bloodjournal.org From 
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Structural anal-ysis qf factor IXG207E-Binding to antithrombin 111. To examine the substrate and/or inhibitor binding pocket of IXaG207E, activated IXG207E was reacted with ATIII that forms a covalent bond to the heavy chain of factor IXa at I : 1 ratio in the presence of heparin. As shown in Fig 5, a complex of molecular weight 1 I O kD was observed at three different concentrations of factor IXa (A) and IXaG207E (B), suggesting that IXaG207E was able to bind ATIII.
Kinetics of activation of factor X . The ability of IXaG207E to cleave its macromolecular substrate, factor X, was examined in an attempt to obtain the experimental kinetic values of IXG207E. Two different concentrations (4 nmol/L and 250 nmol/L) of factor IXa and IXaG207E were incubated with factor X at 37°C over 6 hours in the presence of phospholipids, calcium ions, and the chromogenic substrate for factor X, Spectrozyme Xa. As shown in Fig 6, over the time course studied, IXaG207E was unable to activate factor X. The calculated reaction rate for normal factor IXa at 250 nmol/L was 6.1 X IO-? min" and for IXaG207E, reasons. First, although its level in circulation was 30% to 40% of normal, the abnormal protein is obtainable. Secondly, its mutation was at evolutionally conserved glycine residue that is found at the 207th codon of factor IX and comparable positions of several other serine proteases. These include a number of related coagulant proteins such as factors VII, X, prothrombin, and protein C, as well as trypsin and chymotrypsin. It is inferred that Gly-207 is structurally andor functionally important. Moreover, whereas mutations at the amino-and carboxyl-termini of the catalytic domain of factor IX have been studied extensively:' mutations at and around this region (encoded by the 6th exon) have not been analyzed at the level of the protein. Our biochemical findings show that mutant factor KG207E had a normal electrophoretic mobility on the SDS-PAGE, and reacted normally with at least 4 different MoAbs (A-1, A-4, A-5, and A-7)26 for different regions of factor IX. The protein also bound calcium and was able to undergo subsequent conformational changes. Cleavage of factor IXG207E appeared to be normal by factor XIa or VIIa-TF complex, using either TF from human or bovine thromboplastin (data not shown). Therefore, one can assume that the overall structure of factor IXG207E was not affected by the substitution of glutamic acid at 207. However, the molecule was unable to bind p-aminobenzamidine. Functional analysis showed that factor IXaG207E was a poor enzyme with a reaction rate of one fortieth of that of normal factor IXa with respect to its physiologic substrate, factor X.
Based on what has been established for trypsin and chymotrypsin:2." the critical event during activation of the serine proteases is the formation of the ionic interaction between their positively-charged amino termini and a critical aspartic acid residue (Asp-364 corresponding to Asp-194 of chymotrypsin) to generate the substrate binding pocket (Ser-384 to Gly-386 and Asp-359 to Gln-362 in factor IX).34 In the case of factor IX, conformational rearrangement occurs upon activation by factor XIa or the factor VIIa-TF complex. Assuming similarity of the activation mechanism with the other serine proteases, the newly-generated amino terminal Val-181 would pass through the opening of the activation site pocket to form a salt bridge with the negatively-charged carboxyl group of Asp-364. This rearrangement makes the active site of factor IXa accessible to its physiologic substrate, factor X, the active site inhibitor, p-aminobenzamidine, and to the macromolecular inhibitor, ATIII. Based upon the structural conservation of the serine proteases, we have used the crystal structures of trypsin and other serine proteases to generate a three-dimensional homology model for the heavy chain of factor IXa (Fig 7A) .'X.'s We have used the model to predict the spatial relationships of the catalytic triad of both normal and mutant factor IXa molecules and to estimate the effect of the mutation at a molecular level. Three-dimensional models of factor IX have been useful to predict the effects of point mutations in several studdrophobic core, and its amide proton interacts with the carbonyl oxygen of the active site Ser-365 (at the edge of the active site pocket) through hydrogen bonding (bond length 
Q'
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The mechanism of the defect caused by the mutation at residue 207 is possibly caused by local conformational change. The retained affinity toward the MoAbs against the catalytic domain indicates no significant global change in the structure. The energy-minimized structure of the homologybuilt mutant molecule showed that the hydrogen bond between the amide proton of residue 207 and the carbonyl oxygen of active site residue Ser-365 (residue 195) is conserved in factor IXG207E. However, the hydroxyl group of serine was displaced 2A away from the comparable position in our normal factor IX model. Further examination of this model indicated that introduction of a bulky and negatively charged amino acid at position 207 will also likely affect the conformation of an adjacent loop (residues 362 to 365), and this slight change is likely to be reflected in the catalytic activity. Another possibility is that the structural change caused by this mutation affects an electrostatic interaction between Asp-364 (residue 194) and Val-l81 (residue 1). This interaction occurs upon the activation (the cleavage between residues 180 and 181), which is required for the correct rearrangement of the active site to obtain the catalytic activity. This electrostatic interaction was disrupted in the model of the mutated molecule during the energy minimization. It should be mentioned that the negative charge introduced at residue 207 was not stabilized in the mutant structure. Thus, p-aminobenzamidine failed to monitor the formation of the active site pocket, indicating the activation process did not result in the correct conformation of this pocket. The results from the ATIII binding experiments appear to indicate that a sufficient conformational change occurred in factor IXG207E upon activation that allowed ATIII to bind. However, the molecule failed to bind p-aminobenzamidine and was not able to activate factor X. Several other mutant factor IX molecules have been shown to behave like factor IXG207E in this regard, that they bind ATIII, but not factor X or p-amin~benzamidine.~' It is likely that the requirement for binding factor X is not exactly the same as that for binding ATIII. The interaction between factor M a and factor X is very specific, whereas ATIII, which is less specific for it, is able to form a complex with factor X, factor IX, and thrombin. Whether the structures involved in the ATIII binding are tightly conserved among these three proteins is questionable?' A study by Le Bonniec et a13* showed that a thrombin variant (des-ETW) deleting three amino acid residues (146 through 148) (thrombin des-ETW) failed to bind ATIII efficiently. However, the three amino acids are not conserved among the clotting factors, suggesting a distinct region for ATIII binding in thrombin. Therefore, it is reasonable to predict that factor IX's binding of factor X and ATIII might not be totally identical.
The ability of factor IXG207E to prolong the ox brain PT, a Bm phenotype, was found to be caused by a lower (70%) factor VI1 level in the patient. Purified factor IXG207E did not inhibit the ox brain PT (data not shown). Therefore, it is not likely that factor IXT+iy is a Bm variant. This is consistent with the notion that mutations associated with hemophilia Bm are usually found in the activation pocket region or at the second cleavage site of factor IX (residues 180 and 181).39 Moreover, the patient's older brother, who is also a hemophilia B patient, had a normal level of factor VI1 and did not have a prolonged ox brain PT. Interestingly, the older brother is a moderate hemophilia B who does not require infusion therapy as often as his younger brother. It is not clear that the lower level of factor VI1 contributes to the clinical severity of the younger brother.
According to the annual database for hemophilia B,'" four independent mutations including factor IXTaipery were found at the 207th codon. Arginine is found in two cases (UK43 and Luanda):' a stop codon in one (unnamed),"' and glutamic acid in factor IXTaipeiy.21 All four patients suffer from severe hemophilia B with clotting activities of 1 % (Luanda) or less (the other three). The antigen levels of the two Arg mutants are not reported and that of the stop-codon mutant was less than l%, which was predictable (CRM-). However, the patient with factor IXTaipeip has an antigen level of 30% to 40% ( C M , as does his brother who also suffers from moderate hemophilia B. It is not clear if replacement of Gly-207 by Arg with a positively charged side chain would result in the same CR" phenotype as the Glu mutation in factor IXTaipeiy. Although factor IXG207E tended to be degraded to a higher extent than normal factor IX during purification, how the Glu mutation contributes to the reduced antigen levels of factor IX in the patient is unclear. Using an in vitro expression system, one might be able to address the question of whether the reduced antigen level in factor IXT+iy is caused by increased susceptibility of factor IXG207E to proteolysis or to increased intracellular turnover, and to determine whether differences in the substituted amino acids at this position will affect the CRh4 phenotypes.
